Overview
A Phase 2 randomized, open-label trial to evaluate the safety and efficacy of zimberelimab monotherapy, domvanalimab in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant in front-line non-small cell lung cancer.
Key Eligibility Criteria
- Histologically confirmed squamous or nonsquamous, PD-L1 positive, non-small cell lung cancer that is locally advanced or metastatic
- No sensitizing EGFR or ALK mutation expression